Evidence map›Paper›PMID 25889960›Full record

ArticleMalaria journal2015

Sample size determination for estimating antibody seroconversion rate under stable malaria transmission intensity.

Nuno Sepúlveda, Chris Drakeley

Abstract read
In one paragraph

Article in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Naturally acquired antibody response toFrontiers in cellular and infection microbiology · 2023
    Article
  9. Serological surveillance on potentialFrontiers in cellular and infection microbiology · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nuno SepúlvedaLondon School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. nuno.sepulveda@lshtm.ac.uk.
Chris DrakeleyLondon School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK. chris.drakeley@lshtm.ac.uk.

Funding

Wellcome Trust 091924
6 · The paper itself

Abstract

backgroundIn the last decade, several epidemiological studies have demonstrated the potential of using seroprevalence (SP) and seroconversion rate (SCR) as informative indicators of malaria burden in low transmission settings or in populations on the cusp of elimination. However, most of studies are designed to control ensuing statistical inference over parasite rates and not on these alternative malaria burden measures. SP is in essence a proportion and, thus, many methods exist for the respective sample size determination. In contrast, designing a study where SCR is the primary endpoint, is not an easy task because precision and statistical power are affected by the age distribution of a given population.

methodsTwo sample size calculators for SCR estimation are proposed. The first one consists of transforming the confidence interval for SP into the corresponding one for SCR given a known seroreversion rate (SRR). The second calculator extends the previous one to the most common situation where SRR is unknown. In this situation, data simulation was used together with linear regression in order to study the expected relationship between sample size and precision.

resultsThe performance of the first sample size calculator was studied in terms of the coverage of the confidence intervals for SCR. The results pointed out to eventual problems of under or over coverage for sample sizes ≤250 in very low and high malaria transmission settings (SCR ≤ 0.0036 and SCR ≥ 0.29, respectively). The correct coverage was obtained for the remaining transmission intensities with sample sizes ≥ 50. Sample size determination was then carried out for cross-sectional surveys using realistic SCRs from past sero-epidemiological studies and typical age distributions from African and non-African populations. For SCR < 0.058, African studies require a larger sample size than their non-African counterparts in order to obtain the same precision. The opposite happens for the remaining transmission intensities. With respect to the second sample size calculator, simulation unravelled the likelihood of not having enough information to estimate SRR in low transmission settings (SCR ≤ 0.0108). In that case, the respective estimates tend to underestimate the true SCR. This problem is minimized by sample sizes of no less than 500 individuals. The sample sizes determined by this second method highlighted the prior expectation that, when SRR is not known, sample sizes are increased in relation to the situation of a known SRR. In contrast to the first sample size calculation, African studies would now require lesser individuals than their counterparts conducted elsewhere, irrespective of the transmission intensity.

conclusionsAlthough the proposed sample size calculators can be instrumental to design future cross-sectional surveys, the choice of a particular sample size must be seen as a much broader exercise that involves weighting statistical precision with ethical issues, available human and economic resources, and possible time constraints. Moreover, if the sample size determination is carried out on varying transmission intensities, as done here, the respective sample sizes can also be used in studies comparing sites with different malaria transmission intensities. In conclusion, the proposed sample size calculators are a step towards the design of better sero-epidemiological studies. Their basic ideas show promise to be applied to the planning of alternative sampling schemes that may target or oversample specific age groups.

Indexed as

Epidemiologic MethodsSeroconversionAntibodies, ProtozoanBiostatisticsHumansMalariaSample SizeAntibodies, Protozoan

Identifiers

PMID25889960
PMCPMC4419413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.